NovaBay Pharmaceuticals to Present at the 3rd Annual
LD MICRO Conference

Management to Present at 1:30 PM PST / 4:30 PM EST

EMERYVILLE, CA – December 1, 2010 – NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will deliver a corporate presentation at the LD MICRO Growth Conference on Thursday, December 9th, 2010 at the Luxe Sunset Bel Air in Los Angeles.  The presentation is scheduled for 1:30 PM PST / 4:30 PM EST.

To arrange a meeting with management, please contact Adam Holdsworth at the Investor Relations Group, 212-825-3210, or e-mail adam@investorrelationsgroup.com.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic, anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. NovaBay’s Aganocide® compounds are being developed to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing hospital infections, chronic non-healing wounds, urinary catheter blockage and encrustation (UCBE) and onychomycosis. The company has a license and research collaboration agreement with Alcon, Inc. for use of its Aganocide compounds to treat eye, ear and sinus infections as well as for contact lens care. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in acne, impetigo and other dermatological indications. For more information on NovaBay, visit: www.novabaypharma.com.

About LD Micro

LD MICRO is a by-invitation only newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks as well as comprehensive reports on select companies throughout the year. LD MICRO concentrates on finding, researching, and investing in companies that are overlooked by institutional investors. LD MICRO is a non-registered investment advisor.

Contact:

NovaBay Pharmaceuticals, Inc.
Investors:
Thomas J. Paulson, Chief Financial Officer
510-899-8809
tpaulson@novabaypharma.com

The Investor Relations Group
Investor Relations:
Adam Holdsworth
212-825-3210
adam@investorrelationsgroup.com

Public Relations:
Laura Colontrelle
212-825-3210
laura@investorrelationsgroup.com